Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acrivon Therapeutics, Inc.

5.44
+0.37007.30%
Post-market: 5.440.00000.00%16:05 EDT
Volume:17.86K
Turnover:96.60K
Market Cap:169.38M
PE:-2.11
High:5.46
Open:5.19
Low:5.19
Close:5.07
Loading ...

Acrivon Therapeutics announces FDA granted BDD for ACR-368

TipRanks
·
06 Feb

Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status

Insider Monkey
·
06 Feb

Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation

MT Newswires Live
·
05 Feb

Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification

Dow Jones
·
05 Feb

Acrivon Therapeutics Announces FDA Has Granted Breakthrough Device Designation for Acr-368 Oncosignature Assay for Endometrial Cancer

THOMSON REUTERS
·
05 Feb

Acrivon Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
31 Jan

Acrivon Therapeutics, Inc. (ACRV) Initiated with a Buy at Cantor Fitzgerald

TIPRANKS
·
31 Jan

Cantor Fitzgerald Initiates Acrivon Therapeutics at Overweight

MT Newswires Live
·
31 Jan

Strong Growth Outlook for Acrivon Therapeutics, Inc. Backed by Promising Pipeline and Strategic Advancements

TIPRANKS
·
15 Nov 2024

Oppenheimer Keeps Their Buy Rating on Acrivon Therapeutics, Inc. (ACRV)

TIPRANKS
·
14 Nov 2024

Acrivon Therapeutics, Inc.: Promising Advancements and Strong Buy Rating Backed by Innovative Pipeline and Solid Financial Position

TIPRANKS
·
14 Nov 2024

Acrivon Therapeutics Q3 2024 GAAP EPS $(0.59) Misses $(0.57) Estimate, Cash, Cash Equivalents And Marketable Securities Of $202.8M Expected To Fund Operations Into The Second Half Of 2026

Benzinga
·
13 Nov 2024

Acrivon Therapeutics: Cash, Cash Equivalents & Marketable Securities of $202.8 Mln as of Sept 30, Expected to Fund Operations Into H2 2026

THOMSON REUTERS
·
13 Nov 2024

Acrivon Therapeutics, Inc Q3 Operating Expenses USD 25.14 Million

THOMSON REUTERS
·
13 Nov 2024

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Oct 2024

Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316

MT Newswires Live
·
11 Oct 2024